Friday, December 18, 2009

Tamiflu Infected With the Truth -- How Debilitating to Health of Roche and Gilead Sciences?

Gilead Sciences ($43.20) receives a blended royalty on sales of Tamiflu (oseltamivir), marketed by Roche Holdings. Leveraging global concerns over avian and swine flu, Roche has skillfully raised awareness of the purported need to treat the complications associated with seasonal flu in otherwise healthy adults. The Swiss drug maker’s demonstrated success in challenging the conventional wisdom that “rest and aspirin” be the preferred treatment option for seasonal flu is found in sales of Tamiflu, up 362 percent to $1.93 billion in the first nine months of 2009.

Allegations have surfaced, however, that Roche has misled governments and physicians alike on the actual effectiveness of Tamiflu in preventing complications, such as hospitalization from pneumonia or death, in otherwise healthy people afflicted with the seasonal flu….
Read More at BNET PHARMA….

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.

No comments: